Tennessee Rare Disease Advisory Committee (RDAC)

Minutes 3/22/23

RDAC Members In Attendance: Gillian Hooker, RDAC Secretary, Reginald French, Rizewan Hamid, Terry Jo Bichell, RDAV Vice Chair, Tracy Lovett

Others in Attendance: Yeyberth Lopez, Christine Escamillia (Reata), Holly Murphy (Acadia), AShley McMinn (Vanderbilt), Kerry Engebrecht (RAN), Kemi Olabisi (acadia), Roya Mostafavi (Le Bonheur), Abby Trotter (LifeScienceTN), Gene McCarty (Reata)

Call to order and Welcome	Terry Jo Bichell, RDAC Vice-Chair	
Patient Story - Gaucher Disease	 Yeyberth Lopez Yeyberth Lopez, born in Venezuela, Diagnosed at 5- kept getting sick, nosebleeds, swelling. Went to the emergency room, and was diagnosed by a specialist there. At the time of diagnosis, there was no treatment. In 1997-moved to the US b/c St. Jude had reached out to them b/c they thought it was cancer. When they learned it wasn't cancer, they were referred to Le Bonheur 1999 - started enzyme treatment from Genzyme After treatment - bone pain was much better, not as severe as it used to be, fewer symptoms. She was told she would never be able to have children - but she married her in the US - had a son. 	

As a military wife - limited specialist access - and very few people who knew her disease.	
Was referred to MUSC for delivery of her son, and she had a doctor from TN who also traveled with her.	
Her son was tested at birth and does not have Gaucher.	
Today - if she were to have a baby - she would want to know at birth about Gaucher - She had bone crises, pain, splenectomy,	
With earlier diagnosis, earlier treatment	
For her - as a teenager, had to miss a lot of school for treatment. Pain was a factor in not getting to participate in daily life	
Coverage for therapies is tricky - avoids changing jobs b/c of changes insurance, changing prescriptions	
Sometimes she has to pay out of pocket - there are programs with assistance - needs to be more organized - maybe plans that specialize in rare diseases	
Any metabolic genetics clinic will take on Gauchert - Knoxville, Vanderbilt, Memphis - Hematology	
Enzyme replacement, and oral therapy modifies the lysosomal activity	
Coverage is a huge problem - lots of pre-authorization letters.	
Some plans have no coverage for enzyme therapies or genetic genetic therapies - for gaucher it's been around for a while	
Would be useful to have legislation about coverage for genetic conditions - she also sees her doctors spending a lot of time - would be nice if there was one place to go -	

	 Patient services - get a card top pay for doctors and medicine. R. Hamid- things insurance companies are eager to drop coverage as soon as they can b/c treatment is expensive. Costs are not dropping, they remain very expensive. Also may have limited facilities. 	
Update on TN Diagnostics Network Project	 Ashley McMinn, Project Manager Rizwan Hamid, RDAC Member Talking to the IT team to design the workflow to allow the patient access to the 2nd opinion aspect of the project Once that's ready - presentation to this committee about Website to be launched once the committee gets approval Narrowing scope Sending follow up to Dr. Wu TJ Bichell - presented Project FIND-OUT at ACMG Thinks we should consider Project FINDOUT as an RDAC project Project FINDOUT is thinking about going to the Dept. of Health as a pilot project - it's a research study to understand whether this algorithm The RDAC could endorse this project and also build their diagnostic process as complimentary to FIND-OUT 	-Working group meeting next week -Send follow up to Dr. Wu
Freidrich's Ataxia Therapy	Christine Escamilla, PhD Gene McCarty Reata Pharmaceuticals	Reschedule for future meeting

RDAC Succession Planning	Terry Jo Bichell, RDAC Vice-Chair	
Brief Updates		
Pharmacy Advisory Committee Update (see circulated notes) DUR Update	Reginald French, RDAC Member Tracey Lovett, RDAC Member New Drug approvals in February Next Meeting - May 11 Currently just a skeleton on the website Hutchinson-Guilford Progeria drug on the agenda DUR - April 25th Question about an adrenal insufficiency drug	On the agenda for future discussion - how the RDAC makes recommendations to state and where the RDAC sits in the state
	shortage - worries about drug hoading, etc.	
Department of Intellectual and Development al Disabilities	Terry Jo Bichell, RDAC Vice Chair They had a great method for making recommendations to state Future meetings - would be good to present on method of making recommendations Would we consider inviting a state senator or congress person on our committee At a certain point in the year, every member of the council makes recommendations, council votes on priorities - they compile and those are sent directly to the director of the department of intellectual and developmental disabilities. Then they report on the recommendations	
Poviow of	Progress on the recommendations	
Review of Action Items and Agenda	Scott Strome, RDAC Chair	